Navigation Links
Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
Date:11/7/2013

naloxegol (NKTR-118), an investigational drug candidate, which has completed Phase 3 development as a once- daily, oral tablet for the treatment of opioid-induced constipation. For naloxegol, the MAA in Europe and the NDS in Canada have been accepted for filing, and an NDA has been submitted for filing in the U.S. This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid. NKTR-181, a novel mu-opioid analgesic molecule for chronic pain conditions, has completed Phase 2 development in osteoarthritis patients with chronic knee pain. NKTR-192, a novel mu-opioid analgesic molecule in development to treat acute pain is in Phase 1 clinical development. In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in a number of Phase 2 studies. In anti-infectives, Amikacin Inhale is in Phase 3 studies conducted by Bayer Healthcare to treat patients with Gram-negative pneumonia.

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia. Additional development-stage products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a long-acting PEGylated rFVIII program, which is in Phase 3 clinical development.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Cautionary Note Regarding Forward-Looking StatementsThis press release contains
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... N.J. , Jan. 23, 2015  CytoSorbents Corporation ... commercializing its CytoSorb® extracorporeal cytokine adsorber to reduce ... announced the receipt of $385,642, net of transaction ... of the Technology Business Tax Certificate Transfer Program ...
(Date:1/23/2015)... Jan. 23, 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... in the development and sale of patented biopharmaceutical medicine, ... pharmaceutical ingredients (API) today announced the business and development ... 1. Following the September 2014 JCM application ...
(Date:1/22/2015)... Jan. 22, 2015  ResMed Inc. (NYSE: RMD ) ... Revenue for the quarter was $423.0 million, a 10 percent ... 14 percent increase on a constant currency basis). Net income ... the quarter ended December 31, 2013. Diluted earnings per share ...
Breaking Medicine Technology:CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:Watson Signs Agreement to Divest Equity Interest in ScinoPharm 2Watson Signs Agreement to Divest Equity Interest in ScinoPharm 3Watson Signs Agreement to Divest Equity Interest in ScinoPharm 4Watson Signs Agreement to Divest Equity Interest in ScinoPharm 5HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures 2HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures 3HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures 4HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures 5HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures 6HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures 7
(Date:1/22/2015)... Oceanside,CA (PRWEB) January 22, 2015 For over 20 ... the Oceanside and Vista area has treated just about ... other personal injury circumstances. And for those same twenty-plus years, ... victims of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... Yesterday, Senator Holly Mitchell (D-Los ... Olsen (R-Modesto) were honored by the California Healthcare ... biomedical science, medical device and pharmaceutical innovation in ... “2014 Life Sciences Champion” award from CHI President ...
(Date:1/22/2015)... Payday lending practices in four southern states ... distress to the states that permit them, according to ... on Race and Wealth. , While they generate hundreds ... at the same time substantially depress economic activity, according ...
(Date:1/22/2015)... January 22, 2015 Compare-autoinsurance.org has released a new ... by an auto insurance policy . , Some types ... Clients should check the newly released blog post to see if ... and dangerously damaged vehicles are some of the cars that cannot ...
(Date:12/26/2014)... The US represents the largest market for CRC ... forecast estimates that sales of branded therapies were $2.23 billion. ... high incidence of the disease, high drug treatment rate, and ... Increased sales of CRC therapies over the forecast period will ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... Challenge on First Day ... Illnesses, MINNEAPOLIS, June 5 Just one more hour ... mortality causing,illnesses including obesity, Type 2 diabetes, respiratory disorders and,high ... activities into your day, the sleep experts at Select Comfort(R),(Nasdaq: ...
... Indicator of Failures to Provide Basic Health Care,to Women, ... White,Ribbon Alliance for Safe Motherhood today made public its ... on Africa to invest in,women,s health as necessary to ... childbirth. "While we, too, see tremendous opportunity in,this, the ...
... SAN CARLOS, Calif., June 5 Nuvelo, Inc.,(Nasdaq: ... preclinical data from the,company,s Wnt Therapeutics program showing ... pathway, a signaling pathway that is critical for,cell ... proteins also amplified the activity of Wnt proteins, ...
... Charterhouse Group, Inc.,("Charterhouse") a New York-based ... supported growing middle-market companies since 1973,announced today ... and MTS Health Investors ("MTS") to complete ... ("CEA" or the "Company"), the,market leader in ...
... for Right To ... Red Ball Child Play Program, MORRIS PLAINS, N.J., June 5 ... makers of LISTERINE(R)* to help,Americans bring the benefits of healthy sports ... healthy routines,and physical activity, LISTERINE(R)* and the Hamm brothers are supporting,the ...
... Ticker Symbol: CUR, QUEBEC CITY, June 5 ... company commercializing high-value cancer diagnostic,tests and delivering laboratory ... second quarter 2008 financial results on June 13, ... be followed by a conference,call, which will be ...
Cached Medicine News:Health News:Summer is for Sleeping? Exhausted Americans Challenged to Sleep-in on 'Longest' Day of the Year 2Health News:Summer is for Sleeping? Exhausted Americans Challenged to Sleep-in on 'Longest' Day of the Year 3Health News:White Ribbon Alliance for Safe Motherhood Challenges World Economic Forum on Africa to Invest in Women's Health 2Health News:Nuvelo Announces Publication of Preclinical Data From Wnt Therapeutics Program 2Health News:Nuvelo Announces Publication of Preclinical Data From Wnt Therapeutics Program 3Health News:Charterhouse Group Partners with MTS Health Investors and Highlander Partners to Acquire Chamberlin Edmonds & Associates, Inc., a Leading Provider of Eligibility Services to Hospitals 2Health News:Charterhouse Group Partners with MTS Health Investors and Highlander Partners to Acquire Chamberlin Edmonds & Associates, Inc., a Leading Provider of Eligibility Services to Hospitals 3Health News:Olympic Medalists Paul and Morgan Hamm Challenge Americans to Help Children-in-Need Worldwide 2Health News:Olympic Medalists Paul and Morgan Hamm Challenge Americans to Help Children-in-Need Worldwide 3Health News:Olympic Medalists Paul and Morgan Hamm Challenge Americans to Help Children-in-Need Worldwide 4Health News:DiagnoCure to host Q2 2008 earnings conference call and webcast 2
Mini blades....
... OH3 is a smart system ... available on the market with ... The Leica M520 OH3 is ... range of movement and is ...
Operating microscope with motorized zoom and variable focus up to 405 mm....
Advanced operating microscope with high-resolution apochromatic optics. Senso-servo drive to keep the microscope in perfect balance even if parts are moved or mounted elsewhere....
Medicine Products: